A Pilot Smoking Cessation Study for Newly Diagnosed Lung Cancer Patients
This is a pilot study evaluating the feasibility of a cognitive-behavioral smoking cessation
plus Varenicline program, designed specifically for early stage lung cancer patients and
patients with a potential lung cancer diagnosis pre and post-surgery. The study population
will be approximately 80 smokers who have upcoming lung resection surgery scheduled at
Massachusetts General Hospital (MGH) in Boston. A patient will be considered eligible for
the intervention or control group if he or she 1) is scheduled for a lung resection surgery
with either a lung cancer diagnosis or a potential lung cancer diagnosis, and 2) had a
cigarette in the past 2 weeks, 3) is willing to make a pre-surgical quit attempt. Patients
will be excluded from the control group if they are 1) non-English speaking, 2) determined
medically ineligible by their surgeon/oncologist, 3) suffering from psychosis or dementia 4)
is currently on Varenicline has been on Varenicline for more than 3 weeks, or 5) is
otherwise unable to participate in the intervention. Patients will be excluded from the
intervention group if they are 1) non-English speaking, 2) determined medically ineligible
by their surgeon, 3) suffering from psychosis or dementia 4) have been taking Varenicline
for longer than three weeks 5) have been taking Bupropion (for smoking cessation purposes)
for more than three weeks, 6) is otherwise unable to participate in the intervention.
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Feasibility of recruitment and intervention completion.
Elyse Park, Ph.D.
United States: Institutional Review Board
|Massachusetts General Hospital||Boston, Massachusetts 02114-2617|